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Calcium antagonists and converting enzyme inhibitors reduce
renal injury by different mechanisms
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Calcium antagonists and converting enzyme inhibitors reduce renal
injury by different mechanisms. Both glomerular hypertension and
hypertrophy have been associated with the development of glomerular
injury in models of hypertension and reduced renal mass. The purpose
of this study was to examine the effects of antihypertensive therapy on
these parameters in the remnant kidney model of progressive glomer-
ular sclerosis. Rats underwent 5/6 nephrectomy and were randomly
assigned to receive either no therapy, the calcium entry blocker (CEB),
nifedipine, or the angiotensin converting enzyme inhibitor (CE!), enal-
april. Administration of either drug was associated with a reduction in
systemic blood pressure and in the severity of glomerular injury
assessed eight weeks after renal ablation. Micropuncture studies four
weeks after ablation revealed that systemic and glomerular capillary
pressure were high in untreated remnant kidney rats and reduced by
enalapril, Administration of nifedipine was associated with a decline in
systemic pressure, however, plasma renin levels increased, causing
efferent arteriolar vasoconstriction and persistence of glomerular hy-
pertension. Morphometric analysis showed that kidney weight, glomer-
ular volume and glomerular capillary radius were lower in nifedipine
treated rats than in the other two groups, indicating that the CEB, but
not enalapril, inhibited the hypertrophic response to ablation of renal
mass. Therefore, both CEIs and CEBs reduce glomerular injury in rats
with remnant kidneys but they may act by different mechanisms. CE!
reduce glomerular capillary pressure while CEBs inhibit compensatory
kidney growth.
Many forms of chronic renal disease progress inexorably to
end-stage renal failure. This process has been studied experi-
mentally using rats that have been subjected to extensive
surgical ablation of renal mass. In response to a reduction in
renal mass, the remaining remnant nephrons initially compen-
sate through increases in size and single nephron filtration rate
(SNGFR), however, ultimately they are destroyed [1, 2]. Be-
cause the remnant tissue is normal at the time of ablation, the
eventual destruction of nephrons must be initiated by the
reduction in renal mass itself, and this model may therefore
provide clues to mechanisms of renal damage that are common
to many diseases.
Of the many alterations induced by a reduction in renal mass,
increases in glomerular pressure and size have been identified
as potential contributors to renal damage [2, 3]. Protein restric-
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tion, which both lowers glomerular pressure and limits kidney
growth, reduces injury in a variety of experimental models of
renal disease including the remnant kidney model [2], DOCA-
SALT hypertension [4], the uninephrectomized spontaneously
hypertensive rat (UNX-SHR) [5] and in nephrotoxic serum
nephritis [6]. The administration of converting enzyme inhibi-
tors (CE!) also reduces injury in many of these models, an effect
first linked to a reduction in glomerular pressure [7], but
recently also attributed to inhibition of renal growth [8]. In
contrast, the effects of calcium entry blockers (CEB) have been
less consistent, and both beneficial and adverse effects of these
drugs on glomerular injury have been reported [9, 10]. Because
both classes of drugs are commonly given to patients with
hypertension and renal disease, we compared the effects of a
CE!, enalapril (ENP), to a CEB, nifedipine (NIF), on renal
disease in the remnant kidney model. Both drugs were admin-
istered chronically in doses chosen to normalize systemic blood
pressure. Because both drugs were found to protect the kidney,
glomerular hemodynamics and hypertrophy were assessed to
define the effects of these agents on two probable mediators of
progressive injury.
Methods
Preparation of the model
Male Munich-Wistar rats with an initial weight of 200 to 225
grams were studied. All rats underwent right nephrectomy and
infarction of 2/3 of the left kidney as a one stage procedure. Rats
were anesthetized with pentobarbital (35 mg/kg, i.p.) and placed
on a heated table. The right kidney was exposed via a flank
incision, the renal pedicle ligated, the kidney excised and the
right flank incision closed. The left kidney was then exposed via
a left flank incision. The left renal artery was exposed close to
the kidney and the initial branches of the artery identified.
Two-thirds of the left kidney were then infarcted by tying off
two to three branches of the main renal artery. The left flank
incision was closed and the rats observed until fully conscious.
Three to five days after ablation, plasma creatinine concentra-
tion was determined on tail blood using an autoanalyzer (Cre-
atinine Analyzer 2, Beckman, Somerset, New Jersey, USA)
and rats were randomly assigned to one of three groups.
All rats received standard chow containing 23% protein. The
control (CON, N = 6) group was given tap water to drink. The
second group (ENP, N = 5) received tap water with 50 mg/liter
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enalapril to drink. The third group (NIF, N = 5) received
standard chow to which 0.25% nifedipine by weight had been
added before pelleting. Because nifedipine is light-sensitive,
this group was kept in dark cages.
All measurements except micropuncture studies and plasma
renin concentration (PRC) measurements were performed eight
weeks after surgery. Micropuncture studies and PRC measure-
ments were performed in separate but identically treated groups
of rats four weeks after surgery.
Awake blood pressure and 24-hour protein excretion studies
Biweekly determinations of awake systolic blood pressures
and 24-hour protein excretion rates were made. Systolic blood
pressure was measured with a photoelectric tail cuff device
(Model 29, I.I.T.C., Woodland Hills, California, USA). This
device requires minimal warming of the rat (usually < 15 mm)
prior to blood pressure determination and a brief period of
restraint in a plastic cage. For each animal, the systolic blood
pressure recorded for any given time represented the mean of
four to six pressure recordings obtained at a single sitting.
Twenty-four-hour urine collections were obtained by placing
rats in standard metabolic cages which permitted free access to
food and water.
Whole kidney studies
Standard inulin clearances were performed in rats eight
weeks after ablation. On the day of study, rats were anesthe-
tized with mactin (100 mg/kg, i.p.). A polyethylene catheter
(PE5O) was inserted into the femoral artery and mean arterial
pressure (AP) was measured by a Statham P23B pressure
transducer connected to a Grass recorder (Model 7A, Grass
Instruments, Quincy, Massachusetts, USA). A tracheostomy
was then performed and polyethylene catheters were inserted
into both jugular veins and the left ureter for infusion of test
substances and collection of urine. To compensate for surgical
losses, all rats received an initial intravenous infusion of ison-
cotic rat plasma of equal to 10 mi/kg body wt at a rate of 0.1
mi/mm, followed by a sustained infusion of plasma at a rate of
0,5 mllhr. The rats also received a 0.5 ml intravenous bolus of
inuiin (10 g/l00 ml) in saline followed by an continuous infusion
of 1.0 mi/hr. After a 45-minute equilibration period, two timed
urine collections of fifteen minutes each were made. At the
midpoint of each collection, 100 j of blood were collected in
microhematocrit tubes. Inulin concentration in urine and
plasma was determined by the anthrone method [11] and inulin
clearance was calculated by the standard formula. The kidneys
were then fixed in situ by perfusion for five minutes at the
measured blood pressure with 50 cc of 1.25% glutaraldehyde in
0.1 M cacodylate buffer, excised and weighed.
Analytic techniques
Twenty-four-hour urine output was measured and protein
concentration determined by precipitation with 3% sulfosali-
cylic acid. Turbidity was then determined by measuring absor-
bance at a wavelength of 595A using a Spectronic 501 (Milton
Roy Co., Rochester, New York, USA) spectrophotometer.
Measurements of plasma renin
PRC was measured in separate groups of (CON, N = 5),
(NIF, N = 5) and (ENP, N = 5) four weeks after subtotal renal
ablation. The animals were anesthetized with mactin as de-
scribed above, and a femoral arterial catheter was inserted.
Immediately thereafter, and generally within ten minutes of
induction of anesthesia, 0.5 cc of blood was drawn into a chilled
syringe containing 10 p of EDTA. PRC was measured by the
method of Ballermann, Skorecki and Brenner [121. Briefly, rat
plasma was diluted with maleate buffer to a volume of 500 d
and incubated with 100 tl of plasma obtained from rats 48 hours
after bilateral nephrectomy, to provide an excess of angioten-
sinogen. Specimens were incubated for one hour in a 370water
bath and the generation of angiotensin I was assayed by a
commercially available RIA (New England Nuclear, Boston,
Massachusetts, USA).
Morphometric and morphologic studies
Two coronal slices of each kidney were processed routinely
for light microscopy through paraffin embedding. Sections 3 t
thick were stained with hematoxylin/eosin and periodic acid-
Schiff. The prevalence of glomerular injury was quantitatively
assessed in a blinded fashion by one observer. The percentage
of abnormal giomeruli was calculated for each animal by
dividing the number of abnormal glomeruli by the total number
examined.
Morphometric studies were performed on the same kidney
sections which were examined for morphologic evidence of
glomerular injury. Slides were examined using the Zeiss Inter-
active Digital Analysis System (ZIDAS, Carl Zeiss Inc., Thorn-
wood, New York, USA), and calculations were made based on
standard stereologic principles, as reviewed by Elias, Hennig
and Schwartz [13]. For determination of glomerular volume, the
mean cross-sectional tuft area was obtained by tracing the
outlines of capillary tufts of approximately 75 glomeruli per rat.
In this method, it is assumed that the glomerulus is spherical,
and that the glomerular tuft cross-sectional areas represent
random sections through a population of spheres which are
distributed in a statistically predictable pattern. The area of
each section is dependent on the diameter of the sphere and the
distance of the section from the center of sphere. From the
mean cross-sectional area (Ag), the volume (Vg) can be calcu-
lated by the equation:
Vg = B/k (Ag)312
where B = 1.38, the shape coefficient for spheres, and k = 1.1,
the size distribution coefficient [141.
For determination of the mean glomerular capillary radius
(RGC), the mean capillary cross-sectional area was found by
tracing the luminal areas of all capillaries in a glomerulus falling
within a standard grid. On average, 233 loops per specimen,
representing 8 to 12 glomeruli, were measured. The giomerular
capillary is assumed to be a curved cylinder intersected by the
plane of the slide. For a single animal, the mean area of a
perfectly oriented, perpendicular capillary cross-section is
equal to one-half of the mean of the measured areas of random
sections [13]. The radius is then calculated by the standard
geometric formula.
Micropuncture studies
Micropuncture studies were performed in CON, NIF and
ENP rats four weeks after subtotal nephrectomy. Rats were























systolic pressure in remnant kidney rats. Groups are
Symbols are: (0) CON; () NIF; () ENP. * P < 0.05
anesthetized with 100 mg/kg of mactin i.p., and prepared in the
standard fashion for micropuncture [151. A tracheostomy was
performed and polyethylene catheters inserted into jugular
veins, femoral artery and ureter for infusion of solutions and
collection of samples. The kidney was exposed via a subcostal
incision, placed on a lucite holder and illuminated with a
fiberoptic light. All rats received an initial infusion of isoncotic
plasma equal to 10 mllkg body weight followed by a sustained
infusion of plasma at 0.5 mllhr. Rats also received a 0.5 ml i.v.
bolus of [3H] methoxyinulin followed by a sustained infusion at
a rate of 0.5 mllhr. Mter a 45-minute equilibration period, timed
collections of proximal tubule fluid were obtained by mi-
cropuncture for determination of inulin concentration by liquid
scintillation counting. Urine and plasma content of inulin were
measured by the same method and single nephron glomerular
filtration rate (SNGFR) and glomerular filtration rate (GFR)
were calculated by the standard formulae [151. Efferent arterio-
lar blood samples were obtained for the measurement of total
protein concentration by the method of Viets et a! [16]. Hy-
draulic pressure in glomerular capillaries, cortical tubules and
efferent arterioles was measured directly using the servo-null
micropipette technique [15]. The determinants of ultrafiltration
and segmental vascular resistances were calculated using the
formulae as set out by Baylis et al [15].
Statistics
Statistical analysis of glomerular morphologic abnormalities
was performed by the Kruskal-Wallis test (chi-square approxi-
mation), and for PRC by i-test. For all other data, differences
were analyzed by one way analysis of variance followed by
multiple pairwise comparisons according to the method of
Bonferroni. Data are reported as the mean standard error.
Statistical significance was defined as P < 0.05.
Results
Long-term study
Rats in all three groups gained weight throughout the study.
Mter eight weeks, CON rats weighed 272 7 g while weights
in NIF and ENP rats were 258 11 g and 285 4 g,
respectively. These weights were not significantly different
from one another and suggest that food intake was similar in the
three groups.
As shown in Figure 1, severe, sustained hypertension devel-
oped in CON rats. In contrast, both nifedipine and enalapril
prevented the development of hypertension, and the two drugs
were equally effective in maintaining normal blood pressure
throughout the course of the study.
Values for 24-hour protein excretion are shown in Figure 2.
Baseline values, obtained four to five days after renal ablation,
were normal in all three groups. Four weeks after surgery,
significant proteinuria was present in CON rats and proteinuria
rose progressively during the remainder of the study. Protein
excretion was consistently lower in both NIF and ENP rats
than in CON; at the conclusion of the study, CON rats excreted
73.3 8.4 mg of proteinl24 hr, which was significantly greater
than the 17.9 2.8 mg found in NIF or the 24.3 2.5 mg found
in ENP.
At six and eight weeks after ablation, urine volumes were














Fig. 2. Twenty-four-hour protein excretion rate. Values were deter-
mined in samples collected 8 weeks after ablation. * P<0.05vs. CON.
CON rats excreted an average of 23.6 3.5 cc of urine in 24
hours, significantly greater than either NIF or ENP rats, which
excreted 11.9 2.0 cc and 10.4 1.4 cc, respectively. The
value obtained for the CON group was significantly greater (P <
0.05) than either of the other two groups. At eight weeks,
24-hour urine output averaged 19.1 1.6 cc in CON, 11.2 2.2
cc in NIF and 13.8 2.0 cc in ENP rats. These results suggest
that water intake was greater in CON rats than in either of the
other groups.
In Table 1, values obtained during clearance studies at the
conclusion of the study are given. Inulin clearance was higher in
both NIF and ENP than in CON groups. After perfusion
fixation, the kidney weight of the NIF group was significantly
lower than those found in either of the other groups. This
difference was apparent as well when kidney weight was
corrected for body weight.
Morphologic examination of stained sections revealed that





CON 6 274 7 1.72 0.06 0.58 0.04
NIF 5 258 4 1.17 o.o6 1.14 0.loa
ENP 5 267 18 1.69 0.06 1.07 o.lla
CON NIF ENP
Fig. 3. Prevalence of glomerular sclerosis. The percent of abnormal
glomeruli observed in rats 8 weeks after ablation. * P < 0.05 vs. CON.
both NIF and ENP reduced the prevalence of glomerulosciero-
sis. As shown in Figure 3, the percentage of glomeruli exhibit-
ing segmental or global sclerosis was reduced from 17.8% to
9.0% by ENP and to 2.4% by NIF. While both treatments
reduced the percentage of abnormal glomeruli, only the effect of
nifedipine achieved statistical significance.
Micropuncture studies
The values for weight, hematocrit, mean arterial pressure,
single nephron GFR (SNGFR) and the pressures, flows and
resistances governing ultrafiltration are provided in Table 2.
Weight and hematocrit were similar in all three groups. As
expected, AP was significantly reduced by NIF and ENP in
comparison with CON. SNGFR was elevated in all three groups
in comparison with normal values. Values for SNGFR were
extremely heterogeneous, as reflected by large standard errors,
however, statistically significant differences were found only
between ENP and NIF. Glomerular pressure was elevated in
CON rats and was not reduced by the administration of NIF
despite marked reduction in systemic pressure. In contrast,
ENP reduced both systemic and glomerular pressure signifi-
cantly. These drugs also had disparate effects on renal vascular
resistance; ENP significantly reduced both afferent and efferent
resistance while NIF raised efferent resistance and did not
affect afferent tone. Both glomerular plasma flow and Kf, the
ultrafiltration coefficient, were elevated in ENP compared to
NIF, and contributed to a rise in the SNGFR, offsetting the
reduction in 'GC
Plasma renin measurements
Measurements of PRC are shown in Figure 4. NIF resulted in
a greater than twofold rise in PRC, while ENP raised PRC more
than sixfold. It should be noted that the rise in PRC induced by
CE! is due to inhibition of angiotensin II (Ang II) generation,
while the rise in PRC seen with NIF would be expected to result
in elevated levels of Ang II as well.
Morphometric measurements
As shown in Table 3, NIF reduced glomerular volume by
more than one-third, and glomerular capillary radius by 18% in
comparison to CON. In contrast, ENP had no effect on glomer-
ular hypertrophy as measured by glomerular volume or capil-
lary radius. The suppression in growth conferred by NIF but
not ENP is also supported by the reduction in kidney weight
shown in Table 1.
Discussion
In the present study, subtotal renal ablation resulted in
hypertension, proteinuria and glomerular sclerosis. Both NIF
and ENP reduced systemic blood pressure, lessened protein-
uria and preserved glomerular architecture. However, the ef-
fects of these agents on glomerular size and hemodynamics
differed substantially. ENP reduced systemic and glomerular
pressure, however, had no effect on glomerular size. In con-
trast, NIF failed to lower glomerular pressure, but reduced
hypertrophy as measured by kidney weight, glomerular capil-
lary radius and glomerular volume. These findings suggest that
equally effective protection from progressive renal disease
results from suppression of either hypertrophy or glomerular
hypertension.
The protective effect of CEI's have been documented in
various models of progressive renal disease, including the
remnant model [7], UNX-SHR [17], renal ablation in the Dahl S
rat [18] and diabetes mellitus [19]. These models are character-
ized by both glomerular hypertension and hypertrophy. Ander-
son, Rennke and Brenner [7] postulated that this beneficial
effect of CE! resulted from a reduction in P. They compared
the CE! ENP to a combination of hydralazine, hydrochlorothi-
azide and reserpine (HHR) in the remnant model. While both
regimens were effective in normalizing systemic blood pres-
sure, only ENP reduced glomerular pressure and prevented
glomerular sclerosis and proteinuria. The protective effect of
ENP has also been linked to a reduction in glomerular pressure
in the UNX-SHR [17] and in diabetes mellitus [19]. Recently,
however, the protective effect of CEI has instead been attnb-
uted to attenuation of renal growth. Yoshida et al [8] reported
that both ENP and high-dose HHR reduce injury in the remnant
model and correlated this finding with a reduction in glomerular
size. However, both regimens also reduced glomerular pressure
from control levels previously reported by the same authors [3,
20]. Furthermore, others have found a protective effect of CEI
even when renal growth was unaffected [18]. Therefore, in each
model in which CE! have ameliorated progressive renal injury,
glomerular pressure has been lowered, while no consistent
response of renal growth to these agents has been demon-
strated. In the present study, ENP preserved renal function, as
Table 1. Results of long-term study
Abbreviation C1 is inulin clearance.
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Table 2. Summary of micropuncture data
Group
(N)











g Hct mm Hg dyne . Sec cm5 X 1010
CON 227 41 169 65 14 17 51 5.3 8.4 0.37 0.58 182 484 0.121 0.94 0.49 1.43
(7) ±7 ±1 ±12 ±2 ±1 ±1 ±2 ±0.1 ±0.3 ±0.02 ±0.17 ±37 ±89 ±0.027 ±0.32 ±0.11 ±0.43
NIF 228 45 l36 64 15 18 49 5.3 8.8 0.40 0.52 100 264 0.101 1.09 0.82a 1.92
(8) ±4 ±1 ±5 ±3 ±1 ±1 ±3 ±0.2 ±0.3 ±0.03 ±0.04 ±9 ±37 ±0.023 ±0.16 ±0.08 ±0.22ENP 244 45 108 54a 15 18 39at, 51 77b 0.34 096b 211b 632b 0257ab 031b 025b 055b
(7) ±4 ±1 ±5 ±3 ±1 ±1 ±3 ±0.1 ±0.2 ±0.02 ±0.08 ±17 ±52 ±0.041 ±0.04 ±0.03 ±0.03
(N) injdicates number of animals studied.
a P < 0.05 vs. CONb P < 0.05 vs. NIF
Except where indicated, there were no significant differences between the groups. Abbreviations are in the text.
CON NIF ENP
Fig. 4. Plasma renin concentration (PRC). Values were obtained in
plasma collected 4 weeks after ablation. * P < 0.05 vs. CON.
Group Vg rn3 X c
CON 2.0 ± 0.1 3.8 ± 0.1
NIF 1,2 ± o.la 3.1 ± o,la
ENP 2.0 ± 0.2 3.7 ± 0.1
measured by GFR, and reduced proteinuria. While the preva-
lence of glomeruli with sclerotic lesions was numerically re-
duced by ENP, this change did not achieve statistical signifi-
cance. Nevertheless, when taken together, our data support a
protective effect of ENP on renal function which correlated
with a reduction in glomerular pressure and occurred in the
absence of suppression of growth. These results provide further
confirmation of the role of CE! to slow injury in experimental
renal injury.
In contrast to CE!, the studies of effects of CEB on experi-
mental glomerular injury have been less consistent. We have
reported beneficial effects of NIF in both the UNX-SHR [9] and
in DOCA-SALT hypertension [21]. !n the UNX-SHR, this
protection was linked to a reduction in both GC and kidney
weight [9], while in DOCA-SALT hypertension, glomerular
pressure remained high but glomerular size was reduced [21].
Harris et al [22] and Pelayo et al [23] reported beneficial effects
of the CEB verapamil in the remnant model; this protection
correlated with a decrease in calcium salt deposition and
occurred without a reduction in glomerular pressure. In con-
trast, Brunner et al [10] found that administration of verapamil
to rats with remnant kidneys exacerbated renal injury, and
increased renal size. In the latter study, treatment was begun
several weeks after renal ablation, after the onset of hypertro-
phy and injury. Tolins and Raij compared the CEB TA3090 to
ENP in Dahl S rats after 5/6 renal ablation and found that
glomerular volume was significantly reduced by the CEB when
compared with either control or ENP treated rats [18]. How-
ever, they reported that while ENP prevented glomerular
sclerosis, the CEB only delayed the onset of injury, and
ultimately failed to reduce the severity of glomerular lesions.
The discrepancies between these findings and our own may
have resulted from the use of the remnant Dahl S rat, an
extremely aggressive model of renal disease or from inadequate
dosing of the CEB, as reflected by the failure of TA3090 to
normalize blood pressure.
Previous studies of the effects of CEB on glomerular hemo-
dynamics have been inconsistent, probably reflecting differ-
ences in experimental design and drug dosage. In the perfused
hydronephrotic kidney preparation, in which the renal micro-
vasculature is examined microscopically, CEB preferentially
dilate the afferent arteriole [24]. This suggests that, in the
absence of a change in perfusion pressure, glomerular capillary
pressure would not fall and might even rise in response to CEB.
However, using micropuncture techniques, both Anderson [25]
and Yoshioka et al [20] found that acute infusion of CEB
reduced GC in rats with remnant kidneys. In both studies,
markedly elevated mean arterial pressures were abruptly low-
ered to normal by drug administration. In contrast to the
perfused kidney no change in afferent arteriolar resistance was
found, and efferent resistence either dropped or remained
unchanged. Therefore, in these acute experiments, the fall in
Gc largely resulted from the marked, sudden drop in perfusion
pressure, rather than a specific effect of CEB's on arteriolar
resistance, In contrast, Pelayo et al reported that chronic
administration of the CEB verapamil to RK rats did not alter
segmental resistances or glomerular pressure. However, in this
study, the drug failed to reduce systemic blood pressure and so









Table 3. Morphometric data
Data are mean ± SE. Abbreviations are: Vg, glomerular volume; R0c,
glomerular capillary radius.
aP < 0.05 vs. CON and ENP
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resulted from the low dose that was administered. Neverthe-
less, glomerular injury was reduced, an effect correlated with
decreased calcium salt deposition rather than hemodynamic
alterations.
In previous studies from our own laboratory in other models
of hypertension, chronic administration of NIF in DOCA-
SALT hypertension normalized MAP but did not lower P0
because afferent resistance and systemic pressure fell propor-
tionally in an autoregulatory fashion [211. In contrast, in UNX
SHR NIF caused a significant drop in P that was largely a
consequence of a significant decline in MAP [9]. In summary,
the renal hemodynamic effects of CEB are complex and differ
among experimental models. In addition, both the magnitude
and rapidity of the change in systemic blood pressure and the
baseline level of renal resistance influence the outcome.
In the present study, NIF failed to reduce glomerular capil-
lary pressure. Glomerular hypertension persisted despite nor-
malization of MAP due to a rise in efferent resistance. Because
this hemodynamic pattern is consistent with angiotensin II
induced efferent arteriolar constriction, we examined the effect
of NIF on plasma renin concentration and found more than a
twofold rise.
Reports of the effects of CEB on renin levels have been
contradictory and, like studies of the hemodynamic effects of
these drugs, are influenced by the experimental design, dose
and blood pressure alterations. Renin release injuxtaglomerular
cells is inversely correlated with intracellular calcium concen-
tration [26] and therefore, CEB might be expected to stimulate
renin by blocking calcium entry into these cells. However,
other regulators of renin release, including neurotransmittors
and tubular flow, may also be affected by CEB and the final
PRC would represent the integration of these varied cellular and
hemodynamic effects [26]. We found that NIF, in doses suffi-
cient to normalize blood pressure, increased PRC significantly.
This increased PRC would be expected to augment angiotensin
II generation, leading to efferent arteriolar vasoconstriction and
persistent elevation in glomerular pressure despite decreased
systemic pressure. This hemodynamic pattern is similar to that
found in rats with remnant kidneys given HHR, in which PRC
is also increased [7].
In this study, the beneficial effect of NIF effect on glomerular
injury correlated with a marked suppression of compensatory
hypertrophy as measured by glomerular volume and glomerular
capillary radius. We have previously shown that the inhibition
of compensatory growth by dietary sodium restriction has
similar protective effects in both the remnant model [27] and in
the UNX-SHR [281. As is the case with NIF, sodium restriction
lessens renal damage despite persistently elevated glomerular
pressure.
The mechanisms by which hypertrophy leads to injury are as
yet unknown, and not directly addressed by this study. It has
been suggested that elevations in glomerular capillary radius
and pressure damage the glomerulus by raising vessel wall
tension, a parameter equally dependent on pressure and radius
[28]. In the coronary artery, elevated wall tension enhances
endothelial permeability to albumin [29]. If the glomerular
capillary is similarly affected, elevated wall tension might lead
to proteinuria, increased mesangial trafficking of macromole-
cules and ultimately, to glomerular sclerosis. This hypothesis
provides a plausible explanation for the finding that injury
progresses only when elevations in glomerular pressure and
size coexist, and that the normalization of either parameter
correlates with suppression of injury.
The link between growth and injury could also result from
adverse effects of the growth factors which promote compen-
satory renal growth. For example, renal insulin-like growth
factor I levels are increased in compensatory renal growth [30,
31]. This peptide stimulates proliferation of mesangial cells in
culture. In addition, platelet derived growth factor is increased
in glomeruli from remnant kidneys and correlates with in-
creased matrix production [32]. Therefore, it is possible that the
mesangial cell proliferation and matrix accumulation which
culminate in glomerular sclerosis may result from persistent
stimulation of mesangial cells by growth factors. Further stud-
ies are needed to define the role of these and other growth
factors in the development of glomerular injury and in the
protection afforded by maneuvers that limit growth.
Protection from injury in the remnant model has also been
correlated with suppression of hypertrophy in a recent study by
Boubey et al [33]. They studied the effect of water intake on
renal damage and found that, in rats given large amounts of
water, renal hypertrophy, glomerular sclerosis, blood pressure
and proteinuria were reduced. The authors suggested that these
benefits might have resulted, at least in part, from a decrease in
the urinary concentration process. While we did not measure
urine osmolality or water intake, urine outputs in CON rats
were increased when compared to the treated groups, suggest-
ing that water intake was lower in the treated groups. There-
fore, protection from injury did not depend on increased water
intake and in fact occurred despite a decline in urine output, and
presumably, fluid ingestion.
While we have correlated the protection of NIF with sup-
pression of growth, other potential mechanisms exist. NIF may
inhibit platelet aggregation [34], a maneuver shown to protect
the remnant kidney [35]. However, in a previous study, we
demonstrated that in DOCA-SALT rats given NIF platelet
function was unaffected [21]. Other beneficial effects of CEB
include a decrease in calcium salt accumulation [22] and rever-
sal of renal "hypermetabolism" found in remnant kidneys [36].
Neither parameter was measured in the current study, and it is
possible that, in addition to the suppression of hypertrophy,
these metabolic effects contributed to the amelioration of renal
injury by NIF.
In summary, both NIF and ENP afforded considerable pro-
tection from injury in the rat remnant kidney. The effect of ENP
resulted from reduction in glomerular pressure while NIF
attenuated compensatory renal growth. These findings support
the hypothesis that glomerular hypertrophy and hypertension
are equally important in the genesis of progressive renal injury,
and that each is amenable to pharmacologic manipulation.
Furthermore, because the mechanisms of ENP and NIF differ,
combination therapy with these agents might provide an effec-
tive therapy in experimental and clinical renal disease.
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